Telephone: 519-931-5777, ext. 24152; Fax: 519-931-5789
Article first published online: 20 SEP 2012
Copyright © 2012 AlphaMed Press
Volume 30, Issue 10, pages 2248–2260, October 2012
How to Cite
Putman, D. M., Liu, K. Y., Broughton, H. C., Bell, G. I. and Hess, D. A. (2012), Umbilical Cord Blood-Derived Aldehyde Dehydrogenase-Expressing Progenitor Cells Promote Recovery from Acute Ischemic Injury. STEM CELLS, 30: 2248–2260. doi: 10.1002/stem.1206
Author contributions: D.P.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript; K.L. and G.B.: collection and assembly of data and data analysis and interpretation; H.B.: collection and assembly of data; D.H.: conception and design, financial support, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript.
Disclosure of potential conflicts of interest is found at the end of this article.
First published online in STEM CELLSEXPRESS August 16, 2012.
- Issue published online: 20 SEP 2012
- Article first published online: 20 SEP 2012
- Accepted manuscript online: 16 AUG 2012 02:40PM EST
- Manuscript Accepted: 11 JUL 2012
- Manuscript Received: 24 MAY 2012
- Canadian Institutes of Health Research. Grant Numbers: MOP#86759, grant-in-aid (NA 7295)
- MacDonald scholarship/new investigator salary award
- Heart and Stroke Foundation of Canada
- Canadian Institutes of Health Research studentship
- London Regional Flow Cytometry Facility
- London Regional Genomics Facility
- Hematopoietic progenitors;
- Umbilical cord blood;
- Ischemic disease
Umbilical cord blood (UCB) represents a readily available source of hematopoietic and endothelial precursors at early ontogeny. Understanding the proangiogenic functions of these somatic progenitor subtypes after transplantation is integral to the development of improved cell-based therapies to treat ischemic diseases. We used fluorescence-activated cell sorting to purify a rare (<0.5%) population of UCB cells with high aldehyde dehydrogenase (ALDHhi) activity, a conserved stem/progenitor cell function. ALDHhi cells were depleted of mature monocytes and T- and B-lymphocytes and were enriched for early myeloid (CD33) and stem cell-associated (CD34, CD133, and CD117) phenotypes. Although these cells were primarily hematopoietic in origin, UCB ALDHhi cells demonstrated a proangiogenic transcription profile and were highly enriched for both multipotent myeloid and endothelial colony-forming cells in vitro. Coculture of ALDHhi cells in hanging transwells promoted the survival of human umbilical vein endothelial cells (HUVEC) under growth factor-free and serum-free conditions. On growth factor depleted matrigel, ALDHhi cells significantly increased tube-like cord formation by HUVEC. After induction of acute unilateral hind limb ischemia by femoral artery ligation, transplantation of ALDHhi cells significantly enhanced the recovery of perfusion in ischemic limbs. Despite transient engraftment in the ischemic hind limb, early recruitment of ALDHhi cells into ischemic muscle tissue correlated with increased murine von Willebrand factor blood vessel and CD31+ capillary densities. Thus, UCB ALDHhi cells represent a readily available population of proangiogenic progenitors that promote vascular regeneration. This work provides preclinical justification for the development of therapeutic strategies to treat ischemic diseases using UCB-derived ALDHhi mixed progenitor cells. STEM Cells2012;30:2248–2260